QDELHealthcare · Medical DevicesThe 3 Wall Street analysts covering QuidelOrtho Corp. hold a median 12-month price target of $12 — -9.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores QuidelOrtho Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on QDEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −9.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | Citigroup | Maintains | Neutral | $13 → $18 |
| 1 July 2026 | JP Morgan | Maintains | Underweight | $11 → $12 |
| 7 May 2026 | Jefferies | Downgrade | Hold | — |
| 6 May 2026 | Citigroup | Maintains | Neutral | — |
| 10 Apr 2026 | UBS | Maintains | Neutral | — |
| 12 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 21 Jan 2026 | UBS | Maintains | Neutral | — |
| 7 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 6 Nov 2025 | UBS | Maintains | Neutral | — |
| 7 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 7 Aug 2025 | UBS | Maintains | Neutral | — |
| 6 Aug 2025 | Citigroup | Maintains | Buy | — |
| 8 May 2025 | Jefferies | Upgrade | Buy | — |
| 8 May 2025 | UBS | Maintains | Neutral | — |
| 21 Apr 2025 | JP Morgan | Maintains | Underweight | — |
| 13 Feb 2025 | RBC Capital | Maintains | Outperform | — |
| 13 Feb 2025 | UBS | Maintains | Neutral | — |
| 11 Dec 2024 | Citigroup | Upgrade | Buy | — |
| 10 Dec 2024 | Jefferies | Initiates | Hold | — |
| 19 Sept 2024 | UBS | Upgrade | Neutral | $42 → $50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
QDEL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, QuidelOrtho Corp. returned −50.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 86% of US stocks
Cheaper than 82% of US stocks
Cheaper than 45% of US stocks
Higher than 34% of US stocks
Higher than 40% of US stocks
Higher than 54% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 22% of US stocks
Higher than 45% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
QuidelOrtho Corp. has a market value of $908.6M and an enterprise value of $3.9B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 2.8% year on year.
Net income over the same four quarters: −$1.0B, a −39.2% net margin.
Diluted earnings per share, trailing twelve months: $−15.41.
Free cash flow in the twelve months to 30 June 2026: −$211.2M.
Trailing P/E: −0.8×; forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
QuidelOrtho Corp. employs 6,500 people — $411K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own QuidelOrtho Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
QuidelOrtho released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to help make lab operations smoother amid increasing complexity and testing demand.
Why it matters — The episode highlights QuidelOrtho’s focus on AI and informatics in laboratory operations.
QuidelOrtho said it will release financial results for the third quarter of 2026, ended September 27, shortly after the market closes on November 3, 2026.
Why it matters — QDEL watchers can note the scheduled date and timing for the company’s quarterly results announcement.
QuidelOrtho’s Compensation Committee approved equity awards for two newly hired non-executive employees under its 2026 Inducement Plan. The grants were made as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — The announcement discloses equity awards tied to two new hires, a compensation and hiring-related item for QDEL watchers.
Zacks Investment Research highlighted QuidelOrtho’s strong second-quarter results, diversified product portfolio and cost-saving initiatives as supports for growth prospects, while noting persistent weakness in respiratory demand.
Why it matters — The item identifies both factors supporting QDEL’s prospects and ongoing softness in respiratory demand.
A PRNewsWire item with the headline “Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?” invites shareholders to contact a firm to discuss rights and options at no cost or obligation. The firm says it would handle matters on a contingent-fee basis, with no out-of-pocket payment of legal fees or expenses.
Why it matters — The item raises a question about possible insider fiduciary-duty issues at QuidelOrtho, which may be relevant to shareholders monitoring the company.
The 3 Wall Street analysts covering QuidelOrtho Corp. have a median 12-month price target of $12, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering QuidelOrtho Corp., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks QuidelOrtho Corp. 36 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, QuidelOrtho Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies -9.4% from the last close, and Ticker Nerd's factor model ranks QuidelOrtho Corp. 36 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering QuidelOrtho Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QDEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.
QuidelOrtho Corp. returned -50.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Transforming Data Into Actionable Insights in the Lab". QuidelOrtho released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to help make lab operations smoother amid increasing complexity and testing demand.
QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine. Its offerings are designed to support disease detection, monitoring, and clinical decision-making in settings ranging from hospitals and reference laboratories to blood banks and other care environments. QuidelOrtho serves a global market and plays an important role in providing tools that help clinicians identify infections, manage chronic conditions, and support transfusion safety. Headquartered in San Diego, California, QuidelOrtho Corporation combines broad diagnostic expertise with a diversified portfolio that addresses both routine and specialized testing needs in modern healthcare.
CEO Mr. Brian J. Blaser · 6,500 employees · United States · https://www.quidelortho.com
